Pharvaris reported second-quarter 2026 results alongside a business update centered on deucrictibant, its oral bradykinin B2 receptor antagonist. The company said topline data from CHAPTER-3, a pivotal Phase 3 trial of deucrictibant extended-release for hereditary angioedema prophylaxis, are expected in 3Q2026. It also said the U.S. Food and Drug Administration (FDA, U.S. drug regulator) is reviewing its New Drug Application for deucrictibant immediate-release as an on-demand treatment for HAE attacks, with a PDUFA date of April 23, 2027, while the European Medicines Agency (EMA, EU drug regulator) validated the related marketing application in July 2026. Cash and cash equivalents rose to €318 million as of June 30, 2026, helped by a $132.3 million underwritten offering that the company said extends its cash runway into 2028. Pharvaris posted a second-quarter loss of €47.8 million, compared with €45.5 million a year earlier, as research, development and administrative spending increased.